Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Phase 1, any day now.

<< Previous

Bullboard Posts

Next >>

Comment by PTBaileyon Mar 31, 2022 9:59am

70 Views

Post# 34562614

RE:Phase 1, any day now.

PTBailey wrote: There isn't much reason to not be expecting a NR anytime.

Plus have all the funding they need.

[url=Phase 1 coming any day and have all the funding they need. https://claritaspharma.com/claritas-secures-5-million-equity-financing-facility-with-alumina-partners-ontario-ltd/]Claritas Financing[/url]

<< Previous

Bullboard Posts

Next >>

Get a better understanding of the psychology of options trading